当前位置: 首页 >> 检索结果
242. Glycaemic control is a modifiable risk factor for pancreatic cancer development in patients with diabetes: a population-based cohort study.
作者: Jing Tong Tan.;Xianhua Mao.;David Tak-Wai Lui.;Chang Li.;Ho-Ming Cheng.;Wai-K Leung.;Wai-Kay Seto.;Ka-Shing Cheung.
来源: Gut. 2025年75卷1期94-104页
Effect of glycaemic control on pancreatic cancer (PC) development in patients with long-standing type 2 diabetes (T2D) remains unclear.
244. Setting a vision for British Society of Gastroenterology guidelines: embracing innovation while preserving methodological excellence and clinical utility.
作者: Matthew Kurien.;Elizabeth Bird-Lieberman.;Shahida Din.;Harriet Gordon.;Christopher Andrew Lamb.;Colin J Rees.
来源: Gut. 2025年 246. Gut microbiome comparability between DNA extraction kits.
作者: Gregory R Young.;Nurulamin Noor.;Aryan Khirwadkar.;Lauren C Beck.;Mohmmed Tauseef Sharip.;Kevin Whelan.;Nicholas A Kennedy.;Jack Satsangi.;Julian Marchesi.;Luke Jostins-Dean.;Christopher Stewart.;Paul A Lyons.;Miles Parkes.;Christopher Andrew Lamb.; .
来源: Gut. 2025年 247. Holdemanella biformis augments washed microbiota transplantation for the treatment of radiation enteritis.
作者: Weihong Wang.;You Yu.;Rui Wang.;Yaxue Wang.;Xiao Ding.;Gaochen Lu.;Chen Lu.;Chenchen Liang.;Sheng Zhang.;Bo Yi.;Jianling Bai.;Lizhen Zhang.;Pan Li.;Quan Wen.;Bota Cui.;Faming Zhang.
来源: Gut. 2026年75卷2期289-301页
Current microbiome-based therapeutics face two prominent issues: the limited clinical efficacy of probiotics and the significant variability in the efficacy of microbiota transplantation across different diseases. Although washed microbiota transplantation (WMT) is a new faecal microbiota transplantation, a single therapeutic agent cannot be universally effective for multiple dysbiosis-related diseases.
248. Research priorities for cancers of the oesophagus and stomach: recommendations from a UK and Ireland patient and healthcare professional partnership exercise.
作者: Christopher M Jones.;Wee Han Ng.;Laura Tincknell.;Dylan P McClurg.;Emily Adam.;Pradeep Bhandari.;Karen Campbell.;Pinkie Chambers.;Francesca Ciccarelli.;Helen G Coleman.;Tom Crosby.;Carmel Doyle.;Jason M Dunn.;Jessie Elliott.;Rebecca C Fitzgerald.;Kieran G Foley.;Vicky Goh.;Heike I Grabsch.;Trevor A Graham.;Mike Grocott.;Sarah Gwynne.;Jo Harvey.;Marnix Jansen.;Pernilla Lagergren.;Claire Lamb.;Lauren Leigh-Doyle.;Farida Malik.;Catriona Mayland.;Mimi McCord.;Alan Moss.;Somnath Mukherjee.;Russell Petty.;Siddharth Rananaware.;Joanne Reid.;Gregory Rubin.;Elizabeth Smyth.;Nigel J Trudgill.;Richard C Turkington.;Timothy J Underwood.;Fiona M Walter.;Jessica Williams.;Christopher J Peters.
来源: Gut. 2025年74卷12期1949-1961页
Cancers of the oesophagus and stomach are a major cause of morbidity and mortality. Research is crucial to improving outcomes. However, to maximise value and impact, areas of focus should be prioritised in partnership with patients.
250. Fructose drives colorectal cancer progression by regulating crosstalk between cancer-associated fibroblasts and tumour cells.
作者: Yanfen Cui.;Hui Liu.;Laoming Zhang.;He Zhang.;Zhaosong Wang.;Jiefu Wang.;Zhiyong Wang.;Lanlan Song.;Hui Guo.;Liming Liu.;Weijie Song.;Ruifang Niu.;Fei Zhang.
来源: Gut. 2025年
Fructose has been identified as a potential alternative energy source for cancer cells, facilitated by the fructose-specific transporter GLUT5. Elevated GLUT5 expression in cancer cells has been associated with increased tumour aggressiveness. However, the role of fructose in remodelling the tumour microenvironment, particularly in modulating cancer-associated fibroblast (CAF) behaviour, remains underexplored.
252. Endoscopic Retrograde Cholangiopancreatography (ERCP) services across the UK.
作者: Wafaa Ahmed.;Emily Haworth.;Linda Sharp.;Christina Dobson.;Bettina Kluettgens.;Beverly C Oates.;Kofi Oppong.;Ian Penman.;Colin J Rees.;Simon M Everett.
来源: Gut. 2025年75卷3期 253. Disease-associated hepatocytes are predictive of outcomes and survival in MASLD beyond fibrosis staging.
作者: Rodrigo Carlessi.;Timothy James Kendall.;John K Olynyk.;Benjamin J Dwyer.;Michael C Wallace.;Jonathan A Fallowfield.;Janina Ee Tirnitz-Parker.
来源: Gut. 2025年 254. Sucrase-isomaltase hypomorphic variant Val15Phe affects the response to a sucrose challenge test in patients with IBS.
作者: Andreea Zamfir-Taranu.;Britt-Sabina Löscher.;Andre Franke.;Ferdinando Bonfiglio.;Bodil Ohlsson.;Mauro D'Amato.
来源: Gut. 2025年75卷3期 256. Screening and eradication of Helicobacter pylori for gastric cancer prevention: Taipei Global Consensus II.
作者: Jyh-Ming Liou.;Peter Malfertheiner.;Tzu-Chan Hong.;Hsiu-Chi Cheng.;Kentaro Sugano.;Shailja Shah.;Bor-Shyang Sheu.;Mei-Jyh Chen.;Tsung-Hsien Chiang.;Yi-Chu Chen.;Yoshio Yamaoka.;Sunny H Wong.;Chieh-Chang Chen.;Yeong Yeh Lee.;Duc Trong Quach.;Deng-Chyang Wu.;Ping-I Hsu.;Chun-Ying Wu.;Jeng-Yih Wu.;Jiing-Chyuan Luo.;Wei-Lun Chang.;Hong Lu.;Hidekazu Suzuki.;Hwoon-Yong Jung.;Varocha Mahachai.;Ratha-Korn Vilaichone.;Francis Mégraud.;Jaw-Town Lin.;Khay-Guan Yeoh.;Wai Keung Leung.;Emad M El-Omar.;Yi-Chia Lee.;Ming-Shiang Wu.; .
来源: Gut. 2025年74卷11期1767-1791页
To convene a global consensus on Helicobacter pylori (H pylori) screening and eradication strategies for gastric cancer prevention, identify key knowledge gaps and outline future research directions.
259. Bacteroides intestinalis mediates the sensitivity to irinotecan toxicity via tryptophan catabolites.
作者: Yuanlong Hou.;Hao Wu.;Zhuangyi Zhang.;Jie Wang.;Qifan Chen.;Chunang Lian.;Dandan He.;Ziguang Li.;Wei Wei.;Xin Lin.;Daming Sun.;Baoshan Cao.;Ting Xu.;Mingyuan Cai.;Guangji Wang.;Xueli Zhang.;Liping Duan.;Haiping Hao.;Xiao Zheng.
来源: Gut. 2025年
Late-onset diarrhoea remains a poorly managed concern for clinical irinotecan therapy. Although bacterial β-glucuronidases (β-GUS) mediated SN-38 production is prevailingly thought to mediate intestinal toxicity, β-GUS inhibitors confer limited benefits in the clinic.
|